of at least 30 mL/min/1.73m 2 to 3 different doses of felzartamab or placebo on top of background ...

Mineralys Therapeutics, Inc. (MLYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Mineralys Therapeutics, Inc. (MLYS – Research Report). The ...

New research finds that taking a daily vitamin D supplement may help lower blood pressure, especially for older adults with ...

Mineralys Therapeutics, Inc. ( (MLYS) ) has released its Q3 earnings. Here is a breakdown of the information Mineralys ...

Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering ...

The relationship between pneumonia and cardiovascular disease goes both ways: Pneumonia can increase the risk of heart ...

Introduction Physiology of the Renin-Angiotensin-Aldosterone System and Its Pathophysiologic Role in Some Forms of Hypertension Renin in the Selection of Antihypertensive Drug Therapy Renin as a ...

Pneumonia, frequently intertwined with cardiovascular disease, escalates the risk of heart complications like heart attacks ...

Hypertension affects 1 in 8 adults aged between 20 and 40 years. The prevalence of hypertension among adults in India is ...

Spironolactone, a steroidal aldosterone antagonist, is marketed as a diuretic, but can serve as an antiandrogen if given in high dose. In the US, spironolactone has long been the antiandrogen of ...